Utah Medical Products Inc (UTMD) — Titan Protect Analysis

UTMD

Utah Medical Products Inc

Healthcare · ·

$67.65

Data: 2026-06-03

✓ ETHICAL PASS

NONE MOAT

LIMITED

Data Confidence: 0.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$214M

Total market value of the company

Trailing P/E

19.90

Reasonably valued

Forward P/E

N/A

Based on estimated future earnings — lower means cheaper

Rev Growth

-10.2%

Year-over-year revenue change

Profit Margin

28.9%

How much profit the company keeps from each dollar of revenue

ROE

9.1%

Return on equity — how efficiently it uses shareholder money

Analyst Target

N/A

Recommendation

NONE

Consensus view from ? analysts covering this stock

About Utah Medical Products Inc

Utah Medical Products, Inc. offers medical devices for the healthcare industry in the United States, Europe, and internationally. It offers fetal monitoring accessories, vacuum-assisted delivery systems, and other labor and delivery tools; DISPOSA-HOOD infant respiratory hoods; and DELTRAN PLUS blood pressure monitoring systems. The company provides GESCO, an umbilical vessel catheter, including DIALY-NATE disposable peritoneal dialysis sets; PALA-NATE silicone oral protection devices; URI-CATH

https://www.utahmed.com

Country: United States Employees: 140 Industry: Medical Instruments & Supplies

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% PENDING

Debt must be below 33% of total assets

Cash Ratio

0.0% PENDING

Interest-bearing cash below 33% of assets

Receivables

0.0% PENDING

Receivables below 49% of assets

Revenue Purity

0.0% PENDING

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

ACCUMULATION

Smart money appears to be building positions quietly

Sharpe Ratio

0.223

Positive but modest risk-adjusted returns

Kelly Fraction

0.0074

Marginal edge — very small allocation suggested

Calmar Ratio

0.084

Drawdown risk outweighs the returns — higher risk profile

Annual Return

2.5%

Historical annualised return based on price data

Max Drawdown

-30.1%

Largest peak-to-trough decline — the worst it has been

HMM State

BEAR

Statistical model detects bearish conditions

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

0.37

Very low correlation to market moves

52W High

$71.81

6% below the year high

52W Low

$52.00

30% above the year low

Avg Volume

12,647

Average daily shares traded — higher means easier to buy and sell

Short Ratio

12.2

Days it would take all short sellers to cover — higher means more crowded

Short % Float

N/A

Div Yield

185.0%

Annual dividend as a percentage of the share price

EPS (TTM)

$3.38

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

0.17

Conservative use of debt — low financial risk

Current Ratio

N/A

Quick Ratio

N/A

Like current ratio but excludes inventory — stricter test

Gross Margin

57.9%

Revenue left after cost of goods — higher means pricing power

Operating Margin

34.5%

Profit from core operations before interest and tax

Free Cash Flow

$10M

Positive — the business generates more cash than it spends

Revenue (TTM)

$38M

Total revenue over the last 12 months

Net Income

$11M

Profitable — the bottom line is positive

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-06-03

Before you go